Alfacalcidol Soft Capsules

Alfacalcidol is rapidly converted into 1,25-dihydroxyvitamin D3 in the liver. The latter is a metabolite of vitamin D3 and plays a role in regulating calcium and phosphate metabolism. Since this conversion process is very rapid, the clinical effects of alfacalcidol are basically the same as those of 1,25-dihydroxyvitamin D3. Its main function is to increase the level of 1,25-dihydroxyvitamin D3 in the blood circulation, thereby increasing the intestinal absorption of calcium and phosphate, promoting bone mineralization, reducing plasma parathyroid hormone levels, and reducing bone calcium dissolution, ultimately relieving bone and muscle pain and improving osteoporosis caused by intestinal calcium absorption disorders caused by menopause, aging and endocrine changes.

The main component of this product is alfacalcidol, and its chemical name is (5Z, 7E)-9,10-open-cholesterol-5,7,10(19)-triene-1α,3β-diol.

This product is a reddish-brown (specification 0.25μg) or ivory (specification 1μg) oval opaque soft capsule with "0.25" printed on the front and "1.0" printed on the back of the capsule shell. The content is a yellow oily liquid.

1. Rickets and osteomalacia. 2. Renal osteodystrophy. 3. Osteoporosis. 4. Hypoparathyroidism.

Oral. The first dose for osteoporosis patients is: 0.5μg/day The first dose for all other indications is: Adults: 1μg/day Elderly patients: 0.5μg/day Children weighing more than 20kg without renal osteopathy: 1μg/day In order to prevent the occurrence of hypercalcemia, the dose of alfacalcidol should be adjusted according to biochemical indicators. Blood calcium levels must be measured weekly in the initial stage of medication, and the dose can be gradually increased by 0.25-0.5μg/day. The dose for most adult patients can reach 1-3μg/day. When the dose stabilizes, measure blood calcium every 2-4 weeks. For patients with osteomalacia, the dosage of alfacalcidol should not be increased because their blood calcium levels do not rise rapidly.

Except for causing hypercalcemia and hyperphosphatemia in patients with renal damage, no other adverse reactions have been reported (the possibility of calcium influx in the dialysate should be considered for patients with hypercalcemia undergoing dialysis). However, patients who take the drug in large doses for a long time or suffer from renal damage may experience nausea, dizziness, rash, constipation, anorexia, vomiting, abdominal pain and other signs of hypercalcemia, which will return to normal after stopping the drug.

1. Contraindicated in patients with hypercalcemia, hyperphosphatemia (except those with hypoparathyroidism), and hypermagnesemia. 2. Symptoms of vitamin D poisoning. Patients who are allergic to any ingredient in this product or are known to be allergic to vitamin D and its analogs should not take alfacalcidol.

Patients with hypercalcemia may accelerate arrhythmias when taking digitalis preparations, so the patient's condition must be closely monitored when digitalis preparations are used simultaneously with alfacalcidol. Patients taking barbiturates or other enzyme-inducing anticonvulsants require larger doses of alfacalcidol to produce therapeutic effects. Concomitant use of mineral oil (long-term), cholestyramine, sucralfate, and antacid aluminum preparations may reduce the absorption of alfacalcidol. Concomitant use of magnesium-containing antacid preparations or laxatives with alfacalcidol may cause hypermagnesemia, so it should be used with caution in patients on chronic renal dialysis. Concomitant use of alfacalcidol with calcium-containing preparations and thiazide diuretics may increase the risk of hypercalcemia. Since alfacalcidol is a potent vitamin D inhibitor, it is a good choice for patients with chronic renal dialysis.

Keep in a sealed, dark and cool place. Valid for 36 months.

0.25 μg

36 months